Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom

American Journal of Epidemiology

Volumn 165, Issue 6, 2007, Pages 704-709

  Miller, E ^a   Andrews, N ^a   Stowe, J ^b   Grant, A ^a   Waight, P ^a   Taylor, B ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adverse drug reaction reporting systems; Measles mumps rubella vaccine; Meningitis, aseptic; Seizures; Vaccines

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS VACCINE;

CHILD; HEALTH RISK; MEASLES; MENINGITIS; RISK ASSESSMENT; RISK FACTOR; VACCINATION; VACCINE;

ARTICLE; ASEPTIC MENINGITIS; CONFIDENCE INTERVAL; CONVULSION; DATA BASE; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MENINGITIS; MUMPS; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; UNITED KINGDOM; VACCINATION; VIRUS STRAIN;

ENGLAND; EURASIA; EUROPE; UNITED KINGDOM; WALES; WESTERN EUROPE;

RUBELLA;

EID: 33847339827     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwk045     Document Type: Article

References (16)

1. Furesz J, Contreras G. Vaccine-related mumps meningitis - Canada. Can Dis Wkly Rep 1990;16:253-4.
2. Maguire HC, Begg NT, Handford SG. Meningoencephalitis associated with MMR vaccine. CDR (Lond Engl Rev) 1991;1:R60-1.
3. Colville A, Pugh S. Mumps meningitis and measles, mumps, and rubella vaccine. Lancet 1992;340:786.
4. Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps and rubella vaccine in UK children. Lancet 1993;341:979-82.
5. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995;345:567-9.
6. Balraj V, Miller E. Complications of mumps vaccines. Rev Med Virol 1995;5:219-27.
7. Miller CL. Surveillance after measles vaccination in children. Practitioner 1982;226:535-7.
8. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps and rubella vaccine. N Engl J Med 2001;345:656-61.
9. Folb PI, Bernatowska E, Chen R, et al. A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety. Am J Public Health 2004;94:1926-31.
10. Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997;16:500-3.
11. Afzal MA, Pickford AR, Forsey T, et al. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J Gen Virol 1993;74:917-20.
12. Afzal MA, Pickford AR, Forsey T, et al. Heterogeneous mumps vaccine. Lancet 1992;340:980-1.
13. Nash JQ, Chandrakumar M, Farrington CP, et al. Feasibility study for routine surveillance by record linkage of adverse events attributable to vaccination. Epidemiol Infect 1995;114:475-80.
14. Miller C, Miller E, Rowe K, et al. Surveillance of symptoms following MMR vaccine in children. Practitioner 1989;233:69-73.
15. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20(suppl 1):S58-67.
16. Andrews NJ. Statistical assessment of the association between vaccination and rare adverse events post-licensure. Vaccine 2001;20(suppl 1):S49-53.